{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:01:11Z","timestamp":1746849671512,"version":"3.40.5"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bmc.2025.118165","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:02:06Z","timestamp":1742436126000},"page":"118165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting amyloidogenic proteins through cyclic peptides \u2013 A medicinal chemistry perspective"],"prefix":"10.1016","volume":"123","author":[{"given":"Muhammad Kazim","family":"Zargaham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahsan","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madiha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafeez Mujtaba","family":"Babar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayakumar","family":"Rajadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118165_b0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2025.118165_b0010","unstructured":"Patterson C. World Alzheimer report 2018; 2018."},{"key":"10.1016\/j.bmc.2025.118165_b0015","unstructured":"Organization WH. Global action plan on the public health response to dementia 2017\u20132025; 2017."},{"key":"10.1016\/j.bmc.2025.118165_b0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","article-title":"A close look at BACE1 inhibitors for Alzheimer\u2019s disease treatment","volume":"33","author":"Das","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bmc.2025.118165_b0025","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14506.1","article-title":"Current understanding of Alzheimer\u2019s disease diagnosis and treatment","volume":"7","author":"Weller","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.bmc.2025.118165_b0030","series-title":"Immunotherapy targeting Amyloid-\u03b2 peptides in Alzheimer\u2019s disease","first-page":"23","author":"Zampar","year":"2020"},{"key":"10.1016\/j.bmc.2025.118165_b0035","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/375754a0","article-title":"Cloningof a novel gene bearing missense mutations in early familial Alzheimer disease","volume":"375","author":"Herrington","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118165_b0040","series-title":"Alzheimer\u2019s disease: etiology, neuropathology and pathogenesis","first-page":"1","author":"Sheppard","year":"2020"},{"key":"10.1016\/j.bmc.2025.118165_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-43076-y","article-title":"Synapse loss and progress of Alzheimer\u2019s disease-a network model","volume":"9","author":"Kashyap","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118165_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/ana.10570","article-title":"Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia","author":"Boeve","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bmc.2025.118165_b0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.neuron.2016.12.023","article-title":"Tau pathology induces excitatory neuron loss, grid cell dysfunction, and spatial memory deficits reminiscent of early Alzheimer\u2019s disease","volume":"93","author":"Fu","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.bmc.2025.118165_b0060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.actbio.2020.05.030","article-title":"Collagen hydrogel confinement of Amyloid-\u03b2 (A\u03b2) accelerates aggregation and reduces cytotoxic effects","volume":"112","author":"Simpson","year":"2020","journal-title":"Acta Biomater"},{"key":"10.1016\/j.bmc.2025.118165_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111609","article-title":"Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase","volume":"139","author":"Ahmed","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2025.118165_b0070","article-title":"A\u03b2 plaques","volume":"1","author":"Walker","year":"2020","journal-title":"Free Neuropathol"},{"key":"10.1016\/j.bmc.2025.118165_b0075","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.disamonth.2010.06.001","article-title":"Alzheimer disease","volume":"56","author":"Castellani","year":"2010","journal-title":"Disease-a-Month: DM"},{"key":"10.1016\/j.bmc.2025.118165_b0080","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3389\/fnins.2019.00659","article-title":"Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric A\u03b2 and tau species","volume":"13","author":"Chen","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.bmc.2025.118165_b0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bmc.2025.118165_b0090","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The amyloid-\u03b2 oligomer hypothesis: beginning of the third decade","volume":"64","author":"Cline","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bmc.2025.118165_b0095","doi-asserted-by":"crossref","unstructured":"Nagy A, Polgar T. In-silico targets in neurodegenerative disorders. In Phytochemistry: an in-silico and in-vitro Update. Springer; 2019. p. 403\u201319.","DOI":"10.1007\/978-981-13-6920-9_22"},{"key":"10.1016\/j.bmc.2025.118165_b0100","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3233\/JAD-170543","article-title":"Oxidative stress, amyloid-\u03b2 peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer\u2019s disease","volume":"62","author":"Butterfield","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bmc.2025.118165_b0105","doi-asserted-by":"crossref","first-page":"22532","DOI":"10.1074\/jbc.M115.662908","article-title":"All-trans-retinoic acid reduces BACE1 expression under inflammatory conditions via modulation of nuclear factor \u03baB (NF\u03baB) signaling","volume":"290","author":"Wang","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118165_b0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fnmol.2016.00118","article-title":"Neuronal gene targets of NF-\u03baB and their dysregulation in Alzheimer's disease","volume":"9","author":"Snow","year":"2016","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.bmc.2025.118165_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105192","article-title":"New perspectives on the basal forebrain cholinergic system in Alzheimer\u2019s disease","volume":"150","author":"Berry","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bmc.2025.118165_b0125","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3201644","article-title":"Emerging role of neuron\u2010glia in neurological disorders: at a glance","volume":"2022","author":"Rahman","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.bmc.2025.118165_b0130","doi-asserted-by":"crossref","unstructured":"Dave BP, Shah YB, Maheshwari KG, et al. Pathophysiological aspects and therapeutic armamentarium of Alzheimer\u2019s disease: recent trends and future development. 2023;43(8):3847\u201384.","DOI":"10.1007\/s10571-023-01408-7"},{"key":"10.1016\/j.bmc.2025.118165_b0135","doi-asserted-by":"crossref","unstructured":"Rani S, Dhar SB, Khajuria A, et al. Advanced overview of biomarkers and techniques for early diagnosis of Alzheimer\u2019s disease. 2023;43(6):2491\u2013523.","DOI":"10.1007\/s10571-023-01330-y"},{"key":"10.1016\/j.bmc.2025.118165_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112841","article-title":"Phosphorylated Tau in Alzheimer's disease and other tauopathies","volume":"23","author":"Rawat","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118165_b0145","doi-asserted-by":"crossref","unstructured":"Sen S, Lagas S, Roy A, Kumar HJEJoP. Cytoskeleton saga: its regulation in normal physiology and modulation in neurodegenerative disorders. 2022;925:175001.","DOI":"10.1016\/j.ejphar.2022.175001"},{"key":"10.1016\/j.bmc.2025.118165_b0150","doi-asserted-by":"crossref","unstructured":"Amro Z, Yool AJ, Collins-Praino LEJB, behavior, immunity-health. The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies. 2021;14:100242.","DOI":"10.1016\/j.bbih.2021.100242"},{"key":"10.1016\/j.bmc.2025.118165_b0155","doi-asserted-by":"crossref","unstructured":"Arnsten AF, Datta D, Del Tredici K, Braak HJAs, Dementia. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease. 2021;17(1):115\u201324.","DOI":"10.1002\/alz.12192"},{"key":"10.1016\/j.bmc.2025.118165_b0160","doi-asserted-by":"crossref","unstructured":"Soto-Rojas LO, Pacheco-Herrero M, Mart\u00ednez-G\u00f3mez PA, et al. The neurovascular unit dysfunction in Alzheimer\u2019s disease. 2021;22(4):2022.","DOI":"10.3390\/ijms22042022"},{"key":"10.1016\/j.bmc.2025.118165_b0165","doi-asserted-by":"crossref","unstructured":"Amorim JA, Coppotelli G, Rolo AP, Palmeira CM, Ross JM, Sinclair DAJNRE. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. 2022;18(4):243\u201358.","DOI":"10.1038\/s41574-021-00626-7"},{"key":"10.1016\/j.bmc.2025.118165_b0170","doi-asserted-by":"crossref","unstructured":"Swerdlow RHJJoAsD. The Alzheimer\u2019s disease mitochondrial cascade hypothesis: a current overview. 2023;92(3):751\u201368.","DOI":"10.3233\/JAD-221286"},{"key":"10.1016\/j.bmc.2025.118165_b0175","doi-asserted-by":"crossref","unstructured":"Sun E, Motolani A, Campos L, Lu TJIjoms. The pivotal role of NF-kB in the pathogenesis and therapeutics of Alzheimer\u2019s disease. 2022;23(16):8972.","DOI":"10.3390\/ijms23168972"},{"key":"10.1016\/j.bmc.2025.118165_b0180","doi-asserted-by":"crossref","unstructured":"Sharma VK, Singh TG, Singh S, Garg N, Dhiman SJNr. Apoptotic pathways and Alzheimer\u2019s disease: probing therapeutic potential. 2021;46(12):3103\u201322.","DOI":"10.1007\/s11064-021-03418-7"},{"key":"10.1016\/j.bmc.2025.118165_b0185","doi-asserted-by":"crossref","unstructured":"Jong Huat T, Camats-Perna J, Newcombe EA, et al. The impact of astrocytic NF-\u03baB on healthy and Alzheimer\u2019s disease brains. 2024;14(1):14305.","DOI":"10.1038\/s41598-024-65248-1"},{"key":"10.1016\/j.bmc.2025.118165_b0190","doi-asserted-by":"crossref","unstructured":"Marucci G, Buccioni M, Dal Ben D, Lambertucci C, Volpini R, Amenta FJN. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. 2021;190:108352.","DOI":"10.1016\/j.neuropharm.2020.108352"},{"key":"10.1016\/j.bmc.2025.118165_b0195","doi-asserted-by":"crossref","unstructured":"Rana V, Ghosh S, Bhatt A, Bisht D, Joshi G, Purohit PJCMC. N-Methyl-D-Aspartate (NMDA) receptor antagonists and their pharmacological implication: a medicinal chemistry-oriented perspective outline. 2024;31(29):4725\u201344.","DOI":"10.2174\/0109298673288031240405061759"},{"key":"10.1016\/j.bmc.2025.118165_b0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","article-title":"History and progress of hypotheses and clinical trials for Alzheimer's disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118165_b0205","doi-asserted-by":"crossref","unstructured":"Loeffler DAJJoAsdr. Antibody-mediated clearance of brain amyloid-\u03b2: mechanisms of action, effects of natural and monoclonal anti-A\u03b2 antibodies, and downstream effects. 2023(Preprint):1\u201327.","DOI":"10.3233\/ADR-230025"},{"key":"10.1016\/j.bmc.2025.118165_b0210","doi-asserted-by":"crossref","unstructured":"Chowdhury SJD. Monoclonal antibody treatments for Alzheimer's Disease: Aducanumab and Lecanemab. 2023;11(3):e173.","DOI":"10.15190\/d.2023.12"},{"key":"10.1016\/j.bmc.2025.118165_b0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs: Clin Immunother Biopharm Gene Ther"},{"key":"10.1016\/j.bmc.2025.118165_b0225","doi-asserted-by":"crossref","unstructured":"Buccellato FR, D\u2019Anca M, Tartaglia GM, Del Fabbro M, Scarpini E, Galimberti DJIJoMS. Treatment of Alzheimer\u2019s disease: beyond symptomatic therapies. 2023;24(18):13900.","DOI":"10.3390\/ijms241813900"},{"key":"10.1016\/j.bmc.2025.118165_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/cells13100789","article-title":"Hopping the hurdle: strategies to enhance the molecular delivery to the brain through the blood-brain barrier","volume":"13","author":"Cogill","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bmc.2025.118165_b0235","doi-asserted-by":"crossref","unstructured":"Hartl N, Adams F, Merkel OMJAt. From adsorption to covalent bonding: apolipoprotein E functionalization of polymeric nanoparticles for drug delivery across the blood\u2013brain barrier. 2021;4(1):2000092.","DOI":"10.1002\/adtp.202000092"},{"key":"10.1016\/j.bmc.2025.118165_b0240","doi-asserted-by":"crossref","unstructured":"Kong L, Li X-T, Ni Y-N, et al. Transferrin-modified osthole PEGylated liposomes travel the blood-brain barrier and mitigate Alzheimer\u2019s disease-related pathology in APP\/PS-1 mice. 2020:2841\u201358.","DOI":"10.2147\/IJN.S239608"},{"key":"10.1016\/j.bmc.2025.118165_b0245","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcis.2022.02.124","article-title":"Drug delivery of memantine with carbon dots for Alzheimer\u2019s disease: blood\u2013brain barrier penetration and inhibition of tau aggregation","volume":"617","author":"Zhang","year":"2022","journal-title":"J Colloid Interface Sci"},{"year":"2009","series-title":"Peptides: chemistry and biology","author":"Sewald","key":"10.1016\/j.bmc.2025.118165_b0265"},{"key":"10.1016\/j.bmc.2025.118165_b0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jmgm.2016.12.004","article-title":"Rational design of cyclic peptides to disrupt TGF-\u0392\/SMAD7 signaling in heterotopic ossification","volume":"72","author":"Zhong","year":"2017","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.bmc.2025.118165_b0275","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4155\/fmc.09.23","article-title":"Manufacturing peptides as active pharmaceutical ingredients","volume":"1","author":"Zompra","year":"2009","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2025.118165_b0280","doi-asserted-by":"crossref","first-page":"19249","DOI":"10.1002\/ange.201911900","article-title":"CyClick chemistry for the synthesis of cyclic peptides","volume":"131","author":"Adebomi","year":"2019","journal-title":"Angew Chem"},{"key":"10.1016\/j.bmc.2025.118165_b0285","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cmdc.201402368","article-title":"Receptor\u2010mediated uptake of boron\u2010rich neuropeptide y analogues for boron neutron capture therapy","volume":"10","author":"Ahrens","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118165_b0290","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/med.21639","article-title":"A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies","volume":"40","author":"Jing","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2025.118165_b0295","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1021\/acs.chemrev.0c00013","article-title":"Strategies for fine-tuning the conformations of cyclic peptides","volume":"120","author":"Jwad","year":"2020","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2025.118165_b0300","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/acs.jpcb.7b12419","article-title":"Conformational flexibility is a determinant of permeability for cyclosporin","volume":"122","author":"Wang","year":"2018","journal-title":"J Phys Chem B."},{"key":"10.1016\/j.bmc.2025.118165_b0305","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1021\/ja0563455","article-title":"Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers","volume":"128","author":"Rezai","year":"2006","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2025.118165_b0310","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1039\/C2MD90062A","article-title":"Drugs in middle space","volume":"4","author":"Terrett","year":"2013","journal-title":"MedChemComm."},{"key":"10.1016\/j.bmc.2025.118165_b0315","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/154703a0","article-title":"Gramicidin S and its use in the treatment of infected wounds","volume":"154","author":"Gause","year":"1944","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118165_b0320","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1039\/D0CS00354A","article-title":"Photo-induced radical thiol\u2013ene chemistry: a versatile toolbox for peptide-based drug design","volume":"50","author":"Ahangarpour","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2025.118165_b0325","first-page":"7","article-title":"Cyclic peptides from plants and their promise in drug design","volume":"43","author":"Daly","year":"2012","journal-title":"Aust Biochemist"},{"key":"10.1016\/j.bmc.2025.118165_b0330","series-title":"Peptide applications in biomedicine, biotechnology and bioengineering","first-page":"87","article-title":"Design and applications of cyclic peptides","author":"Claro","year":"2018"},{"key":"10.1016\/j.bmc.2025.118165_b0335","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2012.20.1.019","article-title":"Cyclic peptides as therapeutic agents and biochemical tools","volume":"20","author":"Joo","year":"2012","journal-title":"Biomol Ther"},{"key":"10.1016\/j.bmc.2025.118165_b0340","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1021\/acs.jmedchem.0c01677","article-title":"Facile synthesis of cyclic peptide\u2013phthalocyanine conjugates for epidermal growth factor receptor-targeted photodynamic therapy","volume":"64","author":"Chu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118165_b0355","doi-asserted-by":"crossref","unstructured":"Testa C, D'Addona D, Scrima M, et al. Design, synthesis, and conformational studies of [DOTA]\u2010Octreotide analogs containing [1, 2, 3] triazolyl as a disulfide mimetic. 2018;110(5):e24071.","DOI":"10.1002\/pep2.24071"},{"key":"10.1016\/j.bmc.2025.118165_b0370","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/psc.1141","article-title":"Side chain-to-side chain cyclization by click reaction","volume":"15","author":"Le Chevalier","year":"2009","journal-title":"J Peptide Sci: Off Publ Eur Peptide Soc"},{"key":"10.1016\/j.bmc.2025.118165_b0385","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1016\/j.bmc.2011.08.034","article-title":"Synthesis and evaluation of novel macrocyclic antifungal peptides","volume":"19","author":"Mulder","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118165_b0390","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.tetlet.2017.10.065","article-title":"Cyclic peptide conjugate of curcumin and doxorubicin as an anticancer agent","volume":"58","author":"Darwish","year":"2017","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2025.118165_b0395","doi-asserted-by":"crossref","unstructured":"Li Y-l, Wu M-H, Chang Q, Zhao XJCoNC. Solid-phase synthesis of cyclic octapeptide phakellistatin 15. 2019;55:520\u20134.","DOI":"10.1007\/s10600-019-02729-0"},{"issue":"1","key":"10.1016\/j.bmc.2025.118165_b0405","first-page":"1","article-title":"Design, synthesis and evaluation of linear and cyclic peptide analogues of carnosine as anticancer agents","volume":"2","author":"Tehrani","year":"2019","journal-title":"Int Pharm Acta"},{"key":"10.1016\/j.bmc.2025.118165_b0410","doi-asserted-by":"crossref","unstructured":"Kumar S, Mandal D, El-Mowafi SA, Mozaffari S, Tiwari RK. Click-free synthesis of a multivalent tricyclic peptide as a molecular transporter. 2020;12(9).","DOI":"10.3390\/pharmaceutics12090842"},{"key":"10.1016\/j.bmc.2025.118165_b0415","article-title":"Analogues of a cyclic antimicrobial peptide with a flexible linker show promising activity against Pseudomonas aeruginosa and Staphylococcus aureus","volume":"9","author":"Thomsen","year":"2020","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"10.1016\/j.bmc.2025.118165_b0420","doi-asserted-by":"crossref","unstructured":"Tivari SR, Kokate SV, Sobhia EM, Kumar SG, Shelar UB, Jadeja YSJC. A series of novel bioactive cyclic peptides: synthesis by head\u2010to\u2010tail cyclization approach, antimicrobial activity and molecular docking studies. 2022;7(27):e202201481.","DOI":"10.1002\/slct.202201481"},{"key":"10.1016\/j.bmc.2025.118165_b0425","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1021\/acschemneuro.6b00154","article-title":"Modulation of amyloid \u03b2-protein (A\u03b2) assembly by homologous C-terminal fragments as a strategy for inhibiting a\u03b2 toxicity","volume":"7","author":"Li","year":"2016","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2025.118165_b0430","doi-asserted-by":"crossref","unstructured":"Chenga P-N, Liub C, Zhaob M, Eisenbergb D, Nowicka JS. Amyloid \u03b2-sheet mimics that antagonize amyloid aggregation and reduce amyloid toxicity. 2012;4(11):927\u201333.","DOI":"10.1038\/nchem.1433"},{"key":"10.1016\/j.bmc.2025.118165_b0435","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1021\/ja110545h","article-title":"Macrocyclic \u03b2-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide","volume":"133","author":"Zheng","year":"2011","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2025.118165_b0440","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejmech.2016.01.006","article-title":"Inhibition of tau aggregation using a naturally-occurring cyclic peptide scaffold","volume":"109","author":"Wang","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118165_b0445","doi-asserted-by":"crossref","first-page":"14179","DOI":"10.1021\/ja305416a","article-title":"Heterodivalent linked macrocyclic \u03b2-sheets with enhanced activity against A\u03b2 aggregation: two sites are better than one","volume":"134","author":"Cheng","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2025.118165_b0450","doi-asserted-by":"crossref","first-page":"17338","DOI":"10.1002\/chem.201301535","article-title":"Inhibiting and reversing amyloid\u2010\u03b2 peptide (1\u201340) fibril formation with gramicidin S and engineered analogues","volume":"19","author":"Luo","year":"2013","journal-title":"Chem\u2013Eur J"},{"key":"10.1016\/j.bmc.2025.118165_b0455","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cmdc.201800031","article-title":"Transthyretin mimetics as anti\u2010\u03b2\u2010amyloid agents: a comparison of peptide and protein approaches","volume":"13","author":"Pate","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2025.118165_b0460","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/protein\/gzz016","article-title":"ROSETTA-informed design of structurally stabilized cyclic anti-amyloid peptides","volume":"32","author":"Est","year":"2019","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.bmc.2025.118165_b0465","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1002\/ange.201405109","article-title":"Rational design and identification of a non\u2010peptidic aggregation inhibitor of amyloid\u2010\u03b2 based on a pharmacophore motif obtained from cyclo [\u2010Lys\u2010Leu\u2010Val\u2010Phe\u2010Phe\u2010]","volume":"126","author":"Arai","year":"2014","journal-title":"Angew Chem"},{"key":"10.1016\/j.bmc.2025.118165_b0470","doi-asserted-by":"crossref","first-page":"9902","DOI":"10.1073\/pnas.1422401112","article-title":"Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins","volume":"112","author":"Sormanni","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2025.118165_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-69626-3","article-title":"A rationally designed bicyclic peptide remodels A\u03b242 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer\u2019s disease","volume":"10","author":"Ikenoue","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118165_b0480","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/ja310064v","article-title":"In vitro and mechanistic studies of an antiamyloidogenic self-assembled cyclic d, l-\u03b1-peptide architecture","volume":"135","author":"Richman","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2025.118165_b0485","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10571-008-9298-6","article-title":"p75NTR antagonistic cyclic peptide decreases the size of \u03b2 amyloid-induced brain inflammation","volume":"28","author":"Yaar","year":"2008","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.bmc.2025.118165_b0490","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JAD-190682","article-title":"Maresin1 decreased microglial chemotaxis and ameliorated inflammation induced by amyloid-\u03b2 42 in neuron-microglia co-culture models","volume":"73","author":"Yin","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bmc.2025.118165_b0495","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bmcl.2009.11.092","article-title":"Macrocyclic BACE-1 inhibitors acutely reduce A\u03b2 in brain after po application","volume":"20","author":"Lerchner","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118165_b0500","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.bmcl.2015.05.027","article-title":"Covalent modifier-type aggregation inhibitor of amyloid-\u03b2 based on a cyclo-KLVFF motif","volume":"25","author":"Kino","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118165_b0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-46306-5","article-title":"A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer\u2019s disease","volume":"9","author":"Gibbs","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118165_b0510","article-title":"Epitope scaffolding using alpha-synuclein cyclic peptides to generate oligomer-selective antibodies for Parkinson's disease","author":"Hsueh","year":"2021","journal-title":"bioRxiv."},{"key":"10.1016\/j.bmc.2025.118165_b0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019110","article-title":"A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid \u03b2 and elicits antibodies against oligomeric and fibrillar amyloid and plaques","volume":"6","author":"Hoogerhout","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2025.118165_b0520","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/ADR-200213","article-title":"Vaccination prevented short-term memory loss, but deteriorated long-term spatial memory in Alzheimer\u2019s disease mice, independent of amyloid-\u03b2 pathology","volume":"4","author":"Oberman","year":"2020","journal-title":"J Alzheimer's Dis Rep"},{"key":"10.1016\/j.bmc.2025.118165_b0525","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cbic.200700602","article-title":"A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer's \u03b2\u2010amyloid fibril formation","volume":"9","author":"Dolphin","year":"2008","journal-title":"Chembiochem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T04:28:24Z","timestamp":1746764904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":93,"alternative-id":["S0968089625001063"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118165","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting amyloidogenic proteins through cyclic peptides \u2013 A medicinal chemistry perspective","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118165"}}